The treatment of multidrug-resistant (MDR), extensively drug-resistant or pandrugresistant non-fermenting Gram-negative bacterial infections constitutes a challenge in an era of few new antibiotic choices. This mandates the re-evaluation of already existing antibiotics such as fosfomycin. We systematically reviewed the literature to assess the clinical and microbiological effectiveness of fosfomycin in the treatment of these infections by searching PubMed, Scopus and the Cochrane Library databases. In 23 microbiological studies identified, 1859 MDR non-fermenting Gram-negative bacterial isolates were examined. The susceptibility rate to fosfomycin of MDR Pseudomonas aeruginosa isolates was ≥90% and 50-90% in 7/19 and 4/19 relevant studies, respectively. Cumulatively, 511/1693 (30.2%) MDR P. aeruginosa isolates were susceptible to fosfomycin. Serotype O12 isolates exhibited greater susceptibility. Only 3/85 (3.5%) MDR Acinetobacter baumannii and 0/31 MDR Burkholderia spp. isolates were susceptible to fosfomycin. Variable criteria of susceptibility were used in the included studies. Fosfomycin was synergistic in combination with a -lactam, aminoglycoside or ciprofloxacin in 46/86 (53.5%) MDR P. aeruginosa isolates. One animal study found a good therapeutic effect of the combination fosfomycin/gentamicin against MDR P. aeruginosa endocarditis. In six clinical studies, 33 patients with MDR P. aeruginosa infections (mainly pulmonary exacerbations of cystic fibrosis) received fosfomycin (25/33 in combination with other antibiotics); 91% of the patients clinically improved. In conclusion, fosfomycin could have a role as a therapeutic option against MDR P. aeruginosa infections. Further research is needed to clarify the potential utility of this agent.
Introduction
In an era of extensive bacterial drug resistance, especially among non-fermenting Gram-negative species such as Pseudomonas aeruginosa and Acinetobacter baumannii [1] , emphasis should be given not only to the development of new drugs but also to the re-evaluation of older and 'forgotten' drugs [2] [3] [4] . Fosfomycin is a drug representing the latter category, discovered almost 40 years ago. It inhibits bacterial cell wall biosynthesis by inactivating the UDP-N-acetyl-glucosamine-3-oenolpyruvultransferase [5] .
The oral form of this broad-spectrum antibiotic [6] has principally been used in the treatment of uncomplicated urinary tract infections (UTIs) in the USA, UK and other countries. However, the intravenous form has been used for indications beyond UTIs in only a few countries such as Germany, France, Spain and Japan [7] . Recent data suggest that it may be considered as an alternative in the treatment of Gram-negative and Gram-positive infections other than of UTIs [7, 8] .
Thus, we sought to evaluate human and animal studies that examined the clinical effectiveness and/or microbiological activity of fosfomycin against multidrug-resistant (MDR), extensively drug-resistant (XDR) or pandrug-resistant (PDR) non-fermenting Gram-negative bacilli.
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A c c e p t e d M a n u s c r i p t
Methods

Literature search
We systematically searched PubMed, Scopus and the Cochrane Library databases up to January 2009. The keywords used were (fosfomycin OR phosphomycin OR phosphonomycin) AND (drug resistance OR Pseudomonas OR Acinetobacter OR Stenotrophomonas OR Burkholderia). Bibliographies of relevant articles were also hand-searched.
Study selection
Studies were selected if they included microbiological, animal experimental or clinical data on the effect of fosfomycin against MDR non-fermenting Gram-negative pathogens such as Pseudomonas spp., Acinetobacter spp., Stenotrophomonas spp. and Burkholderia spp. Studies were considered eligible for inclusion if they referred to well defined MDR, XDR or PDR non-fermenting Gram-negative bacilli or to Gram-negative bacilli with resistance to two or more classes of potentially effective antimicrobial agents. The full text was retrieved for articles considered as potentially eligible for inclusion. No limitations were used regarding the study sample size and study design.
Studies written in languages other than English, French, German, Italian or Spanish were excluded from the review as well as studies representing abstracts in scientific conferences.
M a n u s c r i p t
Data extraction
For the microbiological studies, data were extracted regarding the number, site of isolation, resistance characteristics and susceptibility to fosfomycin of the pathogens isolated. Data regarding the antimicrobial effect of the combination of fosfomycin with other antimicrobial agents were also extracted. The fosfomycin minimum inhibitory concentration (MIC) breakpoint values of the relevant standards-developing organisation and the test method(s) used by the authors of each study to define and determine fosfomycin susceptibility were noted. If more than one test method was used to determine fosfomycin susceptibility, data were extracted on all test methods used.
Data were extracted for the clinical and animal studies regarding the study population, type of infection, pathogens isolated, treatment administered and the outcome of infection.
Results
The process of study selection is depicted as a flow diagram in Fig. 1 . A total of 30 studies published between 1985 and 2008 were included in the review . Twentythree of these are microbiological studies on the activity of fosfomycin against clinical isolates of MDR non-fermenting Gram-negative bacteria , one is an animal study [31] and six are clinical studies referring to the treatment of MDR bacterial infections with fosfomycin [32] [33] [34] [35] [36] [37] .
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Microbiological studies
Data extracted from the 23 microbiological studies on the in vitro activity of fosfomycin against MDR non-fermenting Gram-negative bacilli are summarised in Table 1 .
Eleven studies included non-fermenting Gram-negative isolates originating from France [9, 10, 12, 15, 20, [23] [24] [25] [26] 28, 29] , three studies included isolates originating from Japan [11, 17, 18] , two from Italy [19, 30] and one each from Thailand [16] , Taiwan [14] , Greece [8] , Spain [27] , the UK [22] , Germany [21] and Bulgaria [13] . Fifteen of the twenty-three studies reported on the site of isolation of the isolates examined [9, 10, 12, 13, 15, [17] [18] [19] [20] [21] 23, 25, 26, 29, 30] . Ten studies evaluated susceptibility to fosfomycin according to the disk diffusion method [9, 15, 16, 21, [24] [25] [26] [28] [29] [30] and three studies each according to the agar dilution method [8, 12, 20] , the broth microdilution method [17, 18, 27] and Etest [13, 14, 22] , whilst three studies did not state the method of determination of fosfomycin susceptibility [10, 19, 23] . In one study more than one test method was used to determine susceptibility to fosfomycin [11] ; in this study, the Etest method was selected to evaluate fosfomycin susceptibility, as the Clinical and Laboratory Standards Institute (CLSI) does not recommend the relevant broth dilution methods [39] .
Regarding the interpretative MIC breakpoints of susceptibility to fosfomycin used, eight studies used a susceptibility breakpoint of ≤64 mg/L [8, 11, 12, 14, 16, 17, 21, 27] , four studies used a breakpoint of ≤32 mg/L [23, 24, 28, 29] , one study used a breakpoint of ≤16 mg/L [18] , whereas specific data were not reported in 10 studies [9, 10, 13, 15, 19, 20, 22, 25, 26, 30] . The majority of the latter (six of ten) were performed in France [9, 10, 15, 20, 25, 26] . In total, 1859 MDR non-fermenting Gram-negative bacilli M a n u s c r i p t were analysed, of which 1743 (93.8%) were P. aeruginosa isolates [8] [9] [10] [11] [12] [14] [15] [16] [18] [19] [20] [21] [23] [24] [25] [26] [28] [29] [30] , 85 (4.6%) were A. baumannii [8, 13, 17, 27] and 31 (1.7%) were Burkholderia spp. [22] . There was no report on isolates of the Stenotrophomonas spp.
Nineteen studies in total provided data on the susceptibility to fosfomycin of MDR P.
aeruginosa isolates [8] [9] [10] [11] [12] [14] [15] [16] [18] [19] [20] [21] [23] [24] [25] [26] [28] [29] [30] . Seven of these nineteen studies found that ≥90% of the isolates evaluated were susceptible to fosfomycin [10] [11] [12] 19, 21, 23, 29] and four additional studies found that 50-90% of the isolates were susceptible to fosfomycin [8, 15, 24, 28] . Data for the specific susceptibility rate to fosfomycin were available for all but 50 of the 1743 MDR P. aeruginosa isolates evaluated [16] . Cumulatively, 511 (30.2%) of 1693 isolates were found by the individual study authors to be susceptible to fosfomycin.
The great majority of the abovementioned isolates were included in the study conducted by Bert and Lambert-Zechovsky [25] . This study evaluated 1348 P. aeruginosa isolates collected from Intensive Care Unit patients. Although the rate of multidrug resistance of these isolates was not specified, relevant data were included in our review since these demonstrated substantial resistance rates to imipenem (nearly 30%), antipseudomonal penicillins or cephalosporins, aminoglycosides or ciprofloxacin [25] . Moreover, in this study 1604 additional clinical isolates of P. aeruginosa originating from patients located in hospital wards were recovered and examined. The predominant serotypes of the total of 2952 isolates evaluated were O6 (16.2%), O11 (14.6%), O1 (9.8%) and O16 (7.2%).
M a n u s c r i p t
Forty-three (10%) of the 431 P. aeruginosa O11 isolates in contrast to 49 (72.1%) of the 68 P. aeruginosa O12 isolates examined were susceptible to fosfomycin.
Six studies reported on the susceptibility to fosfomycin of a total of 193 P. aeruginosa isolates belonging to serotype O12 [21, 25, 26, [28] [29] [30] . Of the 193 P. aeruginosa O12 isolates examined, 123 (63.7%) were found to be susceptible to fosfomycin. In four of the above six studies that provided specific relevant data, the susceptibility rate to fosfomycin of isolates belonging to other P. aeruginosa serotypes was markedly lower (20.7%) than for isolates of the O12 serotype [25, [28] [29] [30] . In contrast, these isolates had higher rates of susceptibility to antimicrobial agents other than fosfomycin compared with isolates of serotype O12.
Regarding MDR A. baumannii isolates, 3 (3.5%) of the 85 total isolates were susceptible to fosfomycin, as reported in four studies [8, 13, 17, 27] . Regarding Burkholderia spp., none of the 31 isolates examined in one relevant study was found to be susceptible to fosfomycin [22] .
Seven studies reported on the microbiological effect of the combination of fosfomycin with other antibiotics [16, 18, 21, 24, 27, 29, 38] . Among a total of 86 P. aeruginosa MDR isolates, a synergistic effect of the combination of fosfomycin with another antibiotic, either a -lactam (carbapenem, meropenem, imipenem, ceftazidime, aztreonam), an aminoglycoside or ciprofloxacin was shown for 46 isolates (53.5%). Most of the abovementioned 86 isolates were resistant to all of the antibiotics used in combination A c c e p t e d M a n u s c r i p t with fosfomycin. Regarding MDR A. baumannii isolates, one study showed that the combination of fosfomycin with amikacin and tobramycin had a synergistic effect in 15 (44%) of 34 and in 11 (32%) of 34 isolates, respectively, for which fosfomycin alone had no in vitro activity [27] .
Animal studies
One animal experimental study relevant to our review was identified in the literature. A rabbit model of aortic valve endocarditis induced by P. aeruginosa was studied in this in vivo study [31] . The study showed that fosfomycin combined with ciprofloxacin was the best therapeutic option, whereas fosfomycin alone was ineffective and ciprofloxacin was effective only when administered at high doses.
Clinical studies
Data extracted from the six included clinical studies examining fosfomycin therapy for infections caused by non-fermenting Gram-negative bacilli are presented in Table 2 [32 -37] . Specifically, the relevant literature consists of three cohort studies (two conducted in the UK [32, 36] and one in Israel [37] ) and three case reports from Australia [33] , Thailand [35] and Saudi Arabia [34] . A total of 33 patients (17 female) were included in the clinical studies; 26 (78.8%) were adults (15 females) and 7 (21.2%) were juveniles (2 females) [33, 37] . In addition, 31 (93.9%) of the 33 patients were cystic fibrosis (CF) patients (17 female) with pulmonary exacerbation of infectious aetiology [32, 33, 36, 37] . Two of the studies conducted on patients with CF referred to 7 (21.2%) M a n u s c r i p t juveniles (3 females) [33, 37] . All of the six studies referred to infections caused by MDR P. aeruginosa.
Overall, in the clinical studies 33 patients with infections caused by MDR P. aeruginosa received fosfomycin (25 in combination with other antibiotics and 8 as monotherapy). A favourable clinical course was reported with fosfomycin treatment for the great majority of these patients (30/33; 90.9%). Exceptions included one patient in whom fosfomycin treatment was discontinued due to adverse events [36] and two patients who died after the end of fosfomycin treatment [37] . Favourable clinical outcomes were associated with fosfomycin therapy regardless of the susceptibility of the causative pathogens to this agent in one study [36] and despite microbiological persistence of the causative pathogens in an additional study [37] .
Discussion
The main finding of our review is that fosfomycin may play a role in the treatment of infections caused by MDR P. aeruginosa. One has to acknowledge that relatively few studies have examined the clinical or microbiological effects of fosfomycin on infections due to MDR non-fermenting Gram-negative bacilli. Interestingly, the great majority of relevant studies regard P. aeruginosa, whilst there is a dearth of relevant data for MDR A. baumannii, Burkholderia spp. and Stenotrophomonas spp.
The available clinical data indicate that fosfomycin might be an effective and safe drug in patients with severe infections caused by MDR P. aeruginosa. Specifically, the M a n u s c r i p t majority of the evaluated data, derived from studies on CF patients, suggest that fosfomycin may lead to clinical resolution of pulmonary exacerbations caused by MDR P. aeruginosa in these often difficult-to-treat patients, without significant adverse events.
A particular value of fosfomycin for the treatment of infective pulmonary exacerbations in CF, as well as other chronic infections or foreign body-associated infections, may relate to the good penetration and activity of this agent in biofilms [40, 41] .
However, the in vitro data examined in this review showed that less than one-third of the MDR P. aeruginosa isolates were susceptible to fosfomycin. Yet some studies noted that the activity of fosfomycin against P. aeruginosa differed depending on the strain serotype [21, 25, 26, [28] [29] [30] . Specifically, serotype O12 isolates appeared to have substantially higher rates of susceptibility to fosfomycin compared with isolates of other serotypes. This may be important since isolates of serotype O12 are usually associated with a MDR phenotype and have been linked to nosocomial outbreaks in various countries [42, 43] .
It is also noteworthy that in our review the combination of fosfomycin with antibiotics such as carbapenems, ceftazidime, aminoglycosides, aztreonam and ciprofloxacin showed good synergistic effects against the MDR P. aeruginosa isolates tested. This is of special interest as the majority of these MDR P. aeruginosa isolates were resistant to the specific antibiotics mentioned above [16, 18, 24, 29] . Moreover, electron microscopy data have shown that fosfomycin combined with ciprofloxacin induces bacteriolysis in ciprofloxacin-resistant P. aeruginosa isolates [44] . This may provide a rationale to M a n u s c r i p t administer fosfomycin combinations with other antibiotics in MDR P. aeruginosa infections. However, it should be stressed that in clinical practice it is mandatory to perform synergy testing to evaluate the potential benefit of antimicrobial combinations with fosfomycin, as occasionally antagonistic effects have been observed when combining fosfomycin with -lactams or aminoglycosides [16] .
In addition, one of the potential disadvantages of fosfomycin monotherapy is the emergence of resistance during treatment. In this regard, physicians frequently use this medication usually in combination with other antibiotics for the treatment of systemic infections [7] . Data regarding the emergence of resistance to fosfomycin in the studies included in this review were lacking. Yet studies performed in France, where fosfomycin has been used routinely in clinical practice for the treatment of systemic infections, have generally found high rates of resistance of P. aeruginosa isolates to fosfomycin [25, 45] .
However, the latter finding may relate to the lack of universally accepted fosfomycin interpretative MIC breakpoints. The standards-developing organisations that have defined fosfomycin MIC breakpoint values are, amongst others, the British Society for Antimicrobial Chemotherapy (BSAC), the Comité de l'Antibiogramme de la Société Française de Microbiologie (CA-SFM) and the CLSI. Specifically, BSAC suggests a fosfomycin MIC resistance breakpoint of >128 mg/L for Gram-negative rods isolated from UTIs [46] . The CA-SFM suggests a fosfomycin MIC resistance breakpoint of >32 mg/L for Enterobacteriaceae and P. aeruginosa [47] . The CLSI recommends a fosfomycin MIC breakpoint of >64 mg/L for Enterobacteriaceae for use with Escherichia M a n u s c r i p t coli only [39] . The interpretation of susceptibility to fosfomycin in P. aeruginosa isolates may considerably depend on the relevant criteria used, as the MIC mode of P. aeruginosa isolates may correspond to one of the abovementioned breakpoints [45] .
In contrast to MDR P. aeruginosa, A. baumannii was resistant to fosfomycin in the in vitro studies in this review. A synergistic effect with aminoglycosides was reported in one of the included studies. However, the clinical significance, if any, of such a combination remains elusive.
There are several limitations to this review. First, a significant number of studies relevant to our review have been conducted in Japan, where fosfomycin is widely used.
These studies were published in Japanese journals and thus did not fulfil our language criteria. Another limitation is the lack of homogeneity in the definition of MDR, XDR or PDR bacterial infections. For example, one study referred to 'pandrug resistance' in 26 P. aeruginosa isolates, defining it as resistance to -lactams, aminoglycosides and fluoroquinolones [10] . However, this resistance pattern does not signify pandrug resistance [48] . Another limiting factor was also that the authors of the included studies A c c e p t e d M a n u s c r i p t 
